Syntimmune Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.2B

Syntimmune General Information

Description

Operator is a clinical-stage biotechnology platform designed to develop differentiated drug candidates in a wide range of autoimmune diseases. The company's platform leverages a deep understanding of FcRn biology to develop transformative therapies for patients with autoimmune diseases, enabling physicians to get humanized monoclonal antibody that inhibits the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes to improve treatment in a number of rare IgG-mediated diseases.

Contact Information

Website
www.syntimmune.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 116 Huntington Avenue
  • Suite 301
  • Boston, MA 02116
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Acquirer
Alexion
Vertical(s)
Life Sciences
Corporate Office
  • 116 Huntington Avenue
  • Suite 301
  • Boston, MA 02116
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Syntimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 02-Nov-2018 $1.2B Completed Generating Revenue
3. Early Stage VC (Series B) 21-Jun-2017 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 22-Mar-2016 $26M $28M Completed Pre-Clinical Trials
1. Early Stage VC 01-Jan-2014 $2M $2M Completed Startup
To view Syntimmune’s complete valuation and funding history, request access »

Syntimmune Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A
To view Syntimmune’s complete cap table history, request access »

Syntimmune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator is a clinical-stage biotechnology platform designed to develop differentiated drug candidates in a wide range o
Biotechnology
Boston, MA

Nijmegen, Netherlands
 

Fort Lee, NJ
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Syntimmune Competitors (102)

One of Syntimmune’s 102 competitors is Byondis, a Corporation company based in Nijmegen, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Byondis Corporation Nijmegen, Netherlands
Elevar Therapeutics Formerly VC-backed Fort Lee, NJ
Oncorus Formerly VC-backed Andover, MA
EpimAb Biotherapeutics Venture Capital-Backed Shanghai, China
Verastem Formerly VC-backed Needham, MA
You’re viewing 5 of 102 competitors. Get the full list »

Syntimmune Patents

  • 23

    Total Documents Applications and Grants

  • Total Patents Families

  • 14

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Syntimmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190135915-A1 Humanized affinity matured anti-fcrn antibodies Active 25-Apr-2016
AU-2017257680-A1 Humanized affinity matured anti-fcrn antibodies Inactive 25-Apr-2016
ES-2864211-T3 Humanized anti-fcrn antibodies with affinity maturation Active 25-Apr-2016
US-10822417-B2 Humanized affinity matured anti-fcrn antibodies Active 25-Apr-2016
EP-3448429-A1 Humanized affinity matured anti-fcrn antibodies Active 25-Apr-2016 C07K16/28
To view Syntimmune’s complete patent history, request access »

Syntimmune Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Apple Tree Partners (ATP) Venture Capital Minority
Baxalta Ventures Corporate Venture Capital Minority
FMB Research Corporation Minority
Mass General Brigham Innovation Corporate Venture Capital Minority
Mass General Brigham Ventures Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

Syntimmune FAQs

  • When was Syntimmune founded?

    Syntimmune was founded in 2013.

  • Where is Syntimmune headquartered?

    Syntimmune is headquartered in Boston, MA.

  • What industry is Syntimmune in?

    Syntimmune’s primary industry is Biotechnology.

  • Is Syntimmune a private or public company?

    Syntimmune is a Private company.

  • What is the current valuation of Syntimmune?

    The current valuation of Syntimmune is .

  • What is Syntimmune’s current revenue?

    The current revenue for Syntimmune is .

  • How much funding has Syntimmune raised over time?

    Syntimmune has raised $78M.

  • Who are Syntimmune’s investors?

    Apple Tree Partners (ATP), Baxalta Ventures, FMB Research, Mass General Brigham Innovation, and Mass General Brigham Ventures are 5 of 6 investors who have invested in Syntimmune.

  • Who are Syntimmune’s competitors?

    Byondis, Elevar Therapeutics, Oncorus, EpimAb Biotherapeutics, and Verastem are some of the 102 competitors of Syntimmune.

  • When was Syntimmune acquired?

    Syntimmune was acquired on 02-Nov-2018.

  • Who acquired Syntimmune?

    Syntimmune was acquired by Alexion.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »